Keywords: Molecular Imaging, Cancer
Motivation: Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive form of cancer with a low survival rate. Immunotherapies have been able to overcome some of the barriers of traditional therapy with PDAC, resulting in increased survival. However, immunotherapy results in responsive and non-responsive tumors.
Goal(s): This study aims to use MR molecular imaging with a contrast agent that's specific to the tumor microenvironment to determine responders and monitor therapy.
Approach: MR molecular imaging T1w images at discrete timepoints with contrast injection and during therapy.
Results: CNR changes were detected using MR molecular imaging on mice bearing PDAC tumors during a vaccine regimen.
Impact: There is an absence of biomarkers/predictive tools for pancreatic cancer response to immunotherapy. There’s a critical need for therapeutic strategies that improve patient outcomes in tandem with imaging methods that can monitor disease progression and accurately guide clinical decision making.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords